This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access Fragmin® (dalteparin sodium) prescribing information and adverse event reporting can be found at the bottom of the page.

Efficacy and Safety Profile: Treatment of Venous Thromboembolism (VTE)

Lindmarker P et al. Thromb Haemost. 1994;72:186-1901

Study Design:

An open, multicentre, randomised, controlled trial designed to monitor the efficacy and safety of Fragmin compared to UFH in the treatment of venographically confirmed DVT. Once DVT was suspected, UFH could be administered (IV bolus 5,000 IU UFH, followed by an IV infusion 800-1700 IU/hour for a maximum of 24 hours.) During the randomized phase (6-9 days, until INR 2.0-3.0 for 2 consecutive days) the Fragmin cohort received 200 IU/kg SC daily (up to a maximum single daily dose of 18,000 IU) ; the UFH cohort received UFH by infusion, adjusted to maintain aPTT.
Both groups received warfarin on the day of venography  and it was continued for a minimum of 3 months.

Primary endpoint:

Change in Marder scores between venograms obtained before and after treatment. The second venogram (final assessment) was carried out as soon as practical following discontinuation of Fragmin/UFH.

Study Results:

Efficacy: In 94% of Fragmin patients and 92% of UFH patients, the Marder score was improved or unchanged.

Safety: During the trial, there were no reports of a major bleeding occurrence in either group. Minor bleeding was reported in 4 Fragmin patients and 2 UFH patients, out of a total of 196 study participants


Once daily subcutaneous Fragmin injection has been demonstrated to be no less effective than continuous intravenous infusion of UFH in the treatment of DVT, when assessed by Marder score.

Treatment of VTE

Fragmin Tolerability

Find out more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?